Drug Approval | December 23, 2025
FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
SkinMedica redefines luxury skincare with reimagined packaging and new HA5 hydra collagen water burst moisturizer
IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
